Who are Vitekta's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tybost, DARUNAVIR ETHANOLATE, Kaletra, Norvir, RITONAVIR, Lopinavir and ritonavir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/elvitegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Vitekta — Competitive Intelligence Brief

Vitekta (ELVITEGRAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytochrome P450 3A Inhibitor [EPC]. Area: Immunology.

marketed Cytochrome P450 3A Inhibitor [EPC] Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Vitekta (ELVITEGRAVIR) — Gilead Sciences. Vitekta blocks the integrase enzyme, preventing HIV from replicating.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Vitekta TARGET	ELVITEGRAVIR	Gilead Sciences	marketed	Cytochrome P450 3A Inhibitor [EPC]		2012-01-01
Tybost	COBICISTAT	Gilead Sciences	marketed	Cytochrome P450 3A Inhibitor [EPC]	Cytochrome P450 3A	2012-01-01
DARUNAVIR ETHANOLATE	DARUNAVIR ETHANOLATE		marketed	Cytochrome P450 3A Inhibitor [EPC]		2006-01-01
Kaletra	LOPINAVIR	Abbvie Deutschland Gmbh Co. Kg	marketed	Cytochrome P450 3A Inhibitor [EPC]	ATP-binding cassette sub-family G member 2	2000-01-01
Norvir	ritonavir	AbbVie	marketed	Cytochrome P450 3A Inhibitor [EPC]	Cytochrome P450 2C9	1996-01-01
RITONAVIR	RITONAVIR		marketed	Cytochrome P450 3A Inhibitor [EPC]	CYP3A	1996-01-01
Lopinavir and ritonavir	Lopinavir and ritonavir	Centre Hospitalier Universitaire de Saint Etienne	marketed	Cytochrome P450 3A Inhibitor [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytochrome P450 3A Inhibitor [EPC] class)

· 2 drugs in this class
Gilead Sciences · 2 drugs in this class
AbbVie · 1 drug in this class
Abbvie Deutschland Gmbh Co. Kg · 1 drug in this class
Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitekta — Competitive Intelligence Brief. https://druglandscape.com/ci/elvitegravir. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab